It is not often that the way a drug is manufactured becomes the differentiator for selling it, but that is what Biogen Idec ($BIIB) is trying with Eloctate, the antihemophilic factor (recombinant), Fc fusion protein approved last year by the FDA. As the Pharma MedTech Insights blog points out, Biogen Idec has released a four-minute video via the Twitter sponsored feed that explains all of the manufacturing steps it goes through in making and purifying the treatment for hemophilia A. In an email, Biogen Idec spokesperson Andrew Law, explained: "Biogen Idec is committed to listening and acting upon the needs of the hemophilia community. Many people in the hemophilia community are very interested in how therapies are manufactured." Law said the product is manufactured at its facility in Cambridge, MA. The American Society of Hematology points out that in years past, before testing could screen out donors with HIV and hepatitis C, some hemophiliacs got those diseases from their treatments. In the video, Biogen Idec points out that no human- or animal-derived proteins are used in the purification or formulation processes. Eloctate cuts down the number of infusions needed to prevent bleeding episodes, with a dose needed once every three to 5 days instead of the standard two or three a week. It is expected to reach blockbuster status with analysts projecting peak sales of $1.5 billion by 2019. Blog post | Video | More